Patents by Inventor Matthew Mackey
Matthew Mackey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11130758Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: April 10, 2020Date of Patent: September 28, 2021Assignee: Eisai R&D Management Co., Ltd.Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Publication number: 20200347050Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: ApplicationFiled: April 10, 2020Publication date: November 5, 2020Applicant: Eisai R&D Management Co., Ltd.Inventors: Roch BOIVIN, Eric CARLSON, Atsushi ENDO, Hans HANSEN, Lynn D. HAWKINS, Sally ISHIZAKA, Matthew MACKEY, Sridhar NARAYAN, Takashi SATOH, Shawn SCHILLER
-
Patent number: 10640500Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: December 14, 2017Date of Patent: May 5, 2020Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Patent number: 10614958Abstract: A multilayer polymer dielectric film includes a stack of coextruded, alternating first dielectric layers and second dielectric layers that receive electrical charge. The first dielectric layers include a first polymer material and the second dielectric layers include a second polymer material different from the first polymer material. The first polymer material has a permittivity greater than the second polymer material. The second polymer material has a breakdown strength greater than the first polymer material. Adjoining first dielectric layers and second dielectric layers define an interface between the layers that delocalizes electrical charge build-up in the layers. The stack has substantially the crystallographic symmetry before and during receiving electrical charge.Type: GrantFiled: August 30, 2018Date of Patent: April 7, 2020Inventors: Eric Baer, Anne Hiltner, James S. Shirk, Mason Wolak, Zheng Zhou, Matthew Mackey, Joel Carr
-
Publication number: 20190057814Abstract: A multilayer polymer dielectric film includes a stack of coextruded, alternating first dielectric layers and second dielectric layers that receive electrical charge. The first dielectric layers include a first polymer material and the second dielectric layers include a second polymer material different from the first polymer material. The first polymer material has a permittivity greater than the second polymer material. The second polymer material has a breakdown strength greater than the first polymer material. Adjoining first dielectric layers and second dielectric layers define an interface between the layers that delocalizes electrical charge build-up in the layers. The stack has substantially the crystallographic symmetry before and during receiving electrical charge.Type: ApplicationFiled: August 30, 2018Publication date: February 21, 2019Inventors: Eric Baer, Anne Hiltner, James S. Shirk, Mason Wolak, Zheng Zou, Matthew Mackey, Joel Carr
-
Publication number: 20180354939Abstract: Embodiments of the disclosure relate to selectively substituted quinolone compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: ApplicationFiled: August 22, 2018Publication date: December 13, 2018Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: J. Eric Carlson, Hans Hansen, Lynn Hawkins, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Heather Davis, Atsushi Endo
-
Publication number: 20180273532Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: ApplicationFiled: December 14, 2017Publication date: September 27, 2018Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Publication number: 20180030045Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: ApplicationFiled: August 7, 2017Publication date: February 1, 2018Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: J. Eric CARLSON, Hans HANSEN, Lynn HAWKINS, Sally ISHIZAKA, Matthew MACKEY, Shawn SCHILLER, Chikako OGAWA, Heather DAVIS, Atsushi ENDO
-
Patent number: 9850242Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: August 10, 2016Date of Patent: December 26, 2017Assignee: Eisai R&D Management Co., LtdInventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Patent number: 9663486Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: October 14, 2014Date of Patent: May 30, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Roch Boivin, Hans Hansen, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Sridhar Narayan, Peter Bertinato, Gregory Berger, Atsushi Endo, Robert T. Yu, Lynn Hawkins
-
Publication number: 20160339032Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritisType: ApplicationFiled: August 10, 2016Publication date: November 24, 2016Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Publication number: 20160326161Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: ApplicationFiled: July 27, 2016Publication date: November 10, 2016Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Eric CARLSON, Hans HANSEN, Lynn HAWKINS, Sally ISHIZAKA, Matthew MACKEY, Shawn SCHILLER, Chikako OGAWA, Heather DAVIS, Atsushi ENDO
-
Patent number: 9446046Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: July 22, 2015Date of Patent: September 20, 2016Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Patent number: 9428495Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: October 14, 2014Date of Patent: August 30, 2016Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Eric Carlson, Hans Hansen, Lynn Hawkins, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Heather Davis, Atsushi Endo
-
Publication number: 20160176841Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: ApplicationFiled: October 14, 2014Publication date: June 23, 2016Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Roch BOIVIN, Hans HANSEN, Sally ISHIZAKA, Matthew MACKEY, Shawn SCHILLER, Chikako OGAWA, Sridhar NARAYAN, Peter BERTINATO, Gregory BERGER, Atsushi ENDO, Robert T. YU, Lynn HAWKINS
-
Publication number: 20160030430Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritisType: ApplicationFiled: July 22, 2015Publication date: February 4, 2016Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Patent number: 9126999Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: May 31, 2013Date of Patent: September 8, 2015Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Publication number: 20150105370Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: ApplicationFiled: October 14, 2014Publication date: April 16, 2015Inventors: ERIC CARLSON, HANS HANSEN, LYNN HAWKINS, SALLY ISHIZAKA, MATTHEW MACKEY, SHAWN SCHILLER, CHIKAKO OGAWA, HEATHER DAVIS
-
Publication number: 20130324547Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritisType: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
-
Patent number: RE47193Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.Type: GrantFiled: August 4, 2017Date of Patent: January 8, 2019Assignee: Eisai R&D Management Co., Ltd.Inventors: J. Eric Carlson, Hans Hansen, Lynn Hawkins, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Heather Davis, Atsushi Endo